Experimental HCV Drugs
Experimental HCV Drugs
CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Liz Highleyman
All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Presidio
Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.
CROI 2013: Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
- Written by Liz Highleyman
An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the Phase 2a COSMOS trial, according to a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.
Web Design and Development by